A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors
- fireflyannf
- Apr 7
- 1 min read
Phase 1 trial, 230 patients
Trial opened April 2024 in Australia
Expanded to US Locations in September 2024
“Brief Summary
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.”
NOTE: All interventional trials involve risk.
So please consult with your oncology tem as well as ask questions of the trial researchers.
TRIAL NCT06326411
July 2024 Research paper
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
March 2024
FDA Clears IND for NST-628 for Advanced Solid Tumors With RAS-MAPK Mutations
